-

Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures. The company provides complete solutions for gel permeation chromatography (GPC) and size exclusion chromatography (SEC) used in applications to determine the molecular weight and size distribution of macromolecules.

The acquisition broadens and extends Agilent’s product portfolio and customer offerings, particularly in the chemical and biopharmaceutical industries for the analysis of natural and synthetic polymers such as nucleic acids, proteins, monoclonal antibodies, polysaccharides, and synthetic plastic.

“We’re extremely pleased to have the PSS team join Agilent to help us expand our leadership in liquid chromatography and the GPC/SEC market,” said Jacob Thaysen, president, Agilent Life Sciences and Applied Markets Group. “The advanced PSS hardware, software, columns and reference materials we’re adding to our portfolio will enhance our offerings and ensure we deliver the broad spectrum of LC equipment, GPC/SEC analytics and software our customers value.”

By acquiring PSS, Agilent will also add a key software component to complement its lineup of GPC/SEC products. In addition, Agilent will be able to use its global presence to expand the use of PSS products and expertise more widely. Agilent customers in the chemical, biopharmaceutical and other key segments will now also be able to take advantage of PSS technology more broadly because of Agilent’s strong global presence in those markets.

“This is a very strategic move for PSS and Agilent,” said Thorsten Hofe, managing director at PSS. “Together we can provide our customers a full range of GPC and LC products and extend the reach of PSS products into new, fast-growing markets. It’s an exciting time for the PSS team.”

Founded in 1985, PSS is privately held and is based in Mainz, Germany, with additional operations in Amherst, Mass. Financial terms of Agilent’s acquisition of PSS were not disclosed.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent Technologies has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization.
Release Versions

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD...

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’...

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides...
Back to Newsroom